Intra-Cellular Therapies, Inc. with ticker code (ITCI) have now 15 market analysts covering the stock. The analyst consensus now points to a rating of ‘buy’. The target price High/Low ranges between $101.00 and $65.00 and has a mean share price target at $82.84. (at the time of writing). Now with the previous closing price of $71.93 and the analysts are correct then there would likely be a percentage uptick in value of 15.2%. It’s also worth noting that there is a 50 day moving average of $68.81 while the 200 day moving average is $60.99. The total market capitalization for the company now stands at 6.59B. The stock price is currently at: $68.36 USD
The potential market cap would be $7,587,838,815 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of -, revenue per share of $4.84 and a -13.43% return on assets.
Intra-Cellular Therapies, Inc. is a biopharmaceutical company. The Company is focused on the discovery, clinical development and commercialization of small molecule drugs that address underserved medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system (CNS). The Company’s product CAPLYTA is a treatment for depressive episodes associated with bipolar I or II disorder (bipolar depression) in adults as monotherapy and as adjunctive therapy with lithium or valproate. The efficacy of CAPLYTA 42 mg in bipolar depression was demonstrated in two positive Phase III placebo-controlled bipolar depression studies, which evaluated the effects of CAPLYTA on depression in adult patients with bipolar I or bipolar II disorder both as monotherapy (Study 404) and as adjunctive therapy with lithium or valproate (Study 402).
